Please login to the form below

Not currently logged in
Email:
Password:

Melinta names chief medical officer

Sue Cammarata has experience at Shire and Novartis
Meltina Sue Cammarata

Dr Sue Cammarata has joined Melinta Therapeutics as chief medical officer as the company advances the progress of its late-stage pipeline.

In her new role, Dr Cammarata will lead the company's global development and registration strategy, including the plan for lead product candidate delafloxacin, in phase III for skin infections.

She has prior experience in developing anti-infectives, including Cubicin (daptomycin) during her time at Novartis, where she served as VP and global programme head for the company's immunology and infectious disease franchises from 2008 to 2010.

Dr Cammarata spent seven years at Novartis in total, having joined the company from Pharmacia in 2003. At Pharmacia, she worked on the anti-infective Zyvox (linezolid).

Her most recent role prior to joining Melinta was as VP, clinical research at Shire's human genetic therapies division.

Melinta's CEO Mary Szela said: "The extensive expertise Sue gained while developing and commercialising Cubicin and Zyvox, two billion-dollar anti-infective products that are among the most widely prescribed, will be invaluable as we move our earlier stage antimicrobial candidates into and through the clinic." 

26th November 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value: Patient Involvement in Health Technology Assessment
Exploring the evolution of patient involvement in health technology assessment (HTA), and the role of the patient voice in market access....

Infographics